NASDAQ:CYCC - Cyclacel Pharmaceuticals, Inc.
$0.72
 $-0.00
-0.39%
4:00PM EDT
2019-04-18
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CYCC     avg for
industry  
  avg for
sector  
42 stocks weight:  -1000. 00 M 203. 85   241. 91  
42 stocks rank:  4. 45 K 1. 44 K 1. 05 K
# analyst opinions:  3. 00   14. 51   13. 97  

quick ratio:  4. 29   5. 27   1. 81  
current ratio:  4. 45   5. 62   2. 25  

target price low:  0. 60   84. 80   115. 21  
target price avg:  0. 70   111. 51   137. 51  
target price high:  0. 80   135. 81   157. 84  
1-yr high:  1. 64   114. 23   138. 78  
last close:  0. 72   87. 66   116. 69  
50-day avg:  0. 84   95. 54   123. 44  
200-day avg:  1. 11   94. 25   121. 11  
1-yr low:  0. 56   72. 78   98. 34  
volume:  230. 76 K 4. 11 M 8. 07 M
50-day avg volume:  930. 17 K 2. 76 M 5. 02 M
200-day avg volume:  305. 45 K 2. 92 M 4. 59 M

1-day return:  0. 00 % -0. 41 % 0. 07 %
this week return:  -1. 37 % -5. 74 % -4. 11 %
12-wk return:  -4. 00 % 1. 61 % -0. 05 %
52-wk return:  -50. 00 % 3. 12 % 8. 78 %

enterprise value (EV):  -5. 23 M 48. 94 B 114. 64 B
market cap:  12. 34 M 43. 07 B 104. 73 B
EBITDA:  -9. 52 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  0. 55   4. 22   12. 73  
enterprise/revenue (EV/R):  -34. 88   63. 17   12. 84  
total revenue:  150. 00 K 10. 62 B 38. 47 B
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -7. 49 M 2. 20 B 4. 20 B

shares outstanding:  17. 20 M 571. 70 M 1. 24 B
shares:  14. 76 M 571. 81 M 1. 23 B
shares short:  223. 50 K 10. 17 M 13. 00 M
shares short prior month:  162. 62 K 9. 54 M 17. 33 M
short ratio:  0. 12   5. 41   3. 28  
short % of float:  2. 31 % 5. 45 % 2. 38 %
total cash/share:  1. 02   11. 14   9. 33  
total cash:  17. 57 M 6. 71 B 7. 15 B
free cash flow:  -5. 59 M 3. 58 B 2. 96 B
operating cash flow:  -6. 70 M 4. 15 B 4. 30 B

book value:  1. 22   12. 78   26. 92  
price/book:  0. 59   3. 06   -1. 74  
gross profits:  -4. 18 M 8. 04 B 34. 86 B
operating margins:  -6365. 33 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  16. 28 % --- ---
1-yr mean volatility:  -0. 22 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 62   2. 40   4. 10  
forward EPS:  -0. 80   3. 97   7. 13  
P/E:  -1. 16   13. 63   22. 72  
forward P/E:  -0. 90   -15. 95   13. 99  
PE/G:  0. 03   -1. 65   -1. 32  
growth:  -42. 55 % 127. 12 % 29. 61 %
earnings high:  -0. 19   1. 00   1. 66  
earnings avg:  -0. 20   0. 77   1. 53  
earnings low:  -0. 22   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -26. 04 % -2. 75 % 4. 55 %
return on equity:  -39. 35 % -18. 45 % 5. 46 %
revenue/share:  0. 01   13. 29   55. 46  

beta (1yr vs S&P500):  0. 55   1. 25   0. 93  
sharpe (1yr):  -0. 99   0. 37   0. 70  

held % insiders:  13. 53 % 6. 39 % 3. 38 %
held % institutions:  2. 95 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : CYCC
.     + 0.23 =          0.23 :: INITIAL WEIGHT
.   + 36.813 =        37.043 :: spline projection addition
.    x 1.431 =        53.024 :: industry recommendation factor
.    x 0.997 =        52.886 :: return on assets factor
.    x 0.996 =        52.677 :: return on equity factor
.    x 2.791 =       146.997 :: current ratio factor
.    x 1.142 =       167.886 :: quick ratio factor
.    x 2.153 =       361.486 :: short ratio factor
.    x 2.006 =       725.103 :: price-to-book factor
.    x 1.063 =       770.937 :: EBITDA multiple vs industry factor
.    x 5.605 =      4320.896 :: EBITDA multiple factor
.    x 2.158 =      9323.026 :: P/E weight
.    x 2.209 =     20594.184 :: PE/G factor
.    x 1.407 =     28974.225 :: beta factor
.    x 0.992 =     28729.907 :: sharpe factor
.    x 0.959 =     27557.014 :: target low factor
.     x 0.97 =     26742.954 :: target mean factor
.    x 1.033 =     27634.386 :: target high factor
.     x 1.31 =     36197.948 :: industry 2-weeks return factor
.    x 0.893 =     32308.922 :: "drift" penalty 1 days ago
.    x 0.992 =     32052.871 :: overall "drift" factor
.    x 0.837 =     26834.963 :: largest single-day jump factor
.    x 0.061 =      1630.314 :: low price factor
.      x 1.0 =      1630.049 :: factor hist industry gain for week 16
.   cubeRoot =        11.769 :: reduced to standardize
.   - 21.892 =         0.035 :: add/subtract for performance
. -999999999.999 zero/no returns for 11 days out of the past 42x trading days
.                  -999999999.999 :: FINAL WEIGHT for NASDAQ:CYCC


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org